The IASLC 2022 World Conference on Lung Cancer offers a tremendous opportunity to market to one of the largest international gatherings of researchers, clinicians and professionals in the field of lung cancer and thoracic oncology. Over 7,000 clinicians and scientists from around the world are expected to attend. Increase your visibility and organization’s profile by becoming a Sponsor and/or Exhibitor or by holding an Industry Supported Symposium at this outstanding and important Conference.
Amoy Diagnostics Co., Ltd. (SZSE: 300685) is a pioneer and globally leading company in the field of molecular diagnostics for precision oncology, focusing on companion diagnostics product development and commercialization. A rich product portfolio has been established with more than twenty products approved by China NMPA, EU authority, Japan MHLW, South Korea MFDS, etc. Patients in more than 60 countries are benefiting from AmoyDx products. With multiple technological platforms and full capability for companion diagnostics product development and commercialization, AmoyDx has become an important diagnostics partner of many pharmaceutical companies over the globe. For more information, please visit www.amoydiagnostics.com.
Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. The company has six investigational medicines in clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently, HIF-2a. For more information about its clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients. The Company’s focus is on some of the most challenging cancers. Through persistent innovation, AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience. AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.
Blueprint Medicines is a global precision therapy company that aims to invent medicines for people with cancer and hematologic disorders.
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular and neuroscience. Our employees work every day to transform patients’ lives through science.
Caris Life Sciences® (Caris) is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. With a primary focus on cancer, Caris’ suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit www.CarisLifeSciences.com or follow us on Twitter (@CarisLS).
contextflow is your comprehensive solution for all things lung CT: ILD, COPD, and lung cancer. Its clinical decision support system (SEARCH Lung CT), offers quantitative and qualitative analysis of 8 key image patterns and lung nodule detection, segmentation and quantification. By integrating new technology from partner RevealDx, nodules can be further characterized, detecting lung cancer earlier and reducing costs (publication forthcoming). contextflow SEARCH Lung CT includes a TIMELINE feature that even quantifies and visualizes nodules over time, allowing physicians to follow treatment progress easily and efficiently. Fully integrated into the radiologist's workflow, our preliminary research shows average reading time is 31% shorter when contextflow SEARCH Lung CT is available for use (publication forthcoming). See beyond a single case at contextflow.com.
With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly’s commitment to people with cancer, please visit www.LillyOncology.com.
Exelixis is an oncology-focused biotechnology company striving to accelerate discovery, development, and commercialization of new products for difficult-to-treat cancers. Clinical development focuses on continued evaluation of approved products and investigational pipeline. Exelixis continues to invest in expansion of our product pipeline through internal drug discovery and strategic business development opportunities.
The Global Lung Cancer Coalition promotes global understanding of the burden of lung cancer and the right of patients to effective early detection, better treatment and supportive care. Serving as the international voice of lung cancer patients, the Global Lung Cancer Coalition is committed to improving disease outcomes for all.
GSK is focused on maximising patient survival through transformational medicines. GSK’s pipeline is focused on immuno-oncology, cell therapy, tumor cell targeting therapies and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilising modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination.
At Janssen Oncology, our purpose is to make cancer a manageable and, ultimately, curable condition. We understand that the power to change the lives of those living with cancer begins with a very considered step forwards. Whether it’s finding a novel solution, a new indication approval, or even just reaching one more patient. That’s The Power of Purpose™.
Medscape is the leading source of clinical news, health information, medical education and point-of-care tools for health care professionals across more than 30 specialty areas. Medscape offers specialists, primary care physicians, and other health professionals the most robust and integrated medical information and educational tools.
Merck KGaA, Darmstadt, Germany is a science-led organization dedicated to delivering transformative medicines with the goal of making a meaningful difference in the lives of people affected by cancer. Our oncology research efforts aim to leverage our synergistic portfolio in oncogenic pathways, immuno-oncology, and DNA Damage Response (DDR) to tackle challenging tumor types in gastrointestinal, genitourinary, and thoracic cancers. Our curiosity drives our pursuit of treatments for even the most complex cancers, as we work to illuminate a path to scientific breakthroughs that transform patient outcomes. Learn more at www.merckgrouponcology.com.
MeVis Medical Solutions AG develops software for the analysis and processing of medical imaging data. Focus is the image-based early detection of cancer. Its state-of-the-art software solutions support the image-based early detection of lung cancer with dedicated reading software and how it can be used in lung cancer screening settings.
Mirati Therapeutics, Inc. is a clinical-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer.
At MSD, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer, MSD is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com/
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields, TTFields. TTFields are electric fields that disrupt cancer cell division. Novocure’s commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer. Today, we have an industry-leading portfolio of 24 approved innovative cancer medicines and biosimilars across more than 30 indications. Going forward, we are focused on delivering a next wave of breakthroughs in breast cancer, genitourinary cancer, hematology and precision medicine.
Since 2007, Sanofi and Regeneron have collaborated to help people with conditions that are often difficult to diagnose and treat, using innovative technology platforms. Sanofi is an innovative global healthcare company that provides potentially life-changing treatment options and life-saving vaccine protection to millions of people globally. Regeneron is a leading science-based biopharmaceutical company that invents, develops and commercializes medicines to treat serious medical conditions.
Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future. For additional information on Spectrum Pharmaceuticals please visit www.sppirx.com
Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner, and safer. Our clinical next-generation sequencing (NGS) division focuses on delivering simple, fast and cost effective NGS technology for a range of applications. We are enabling precision oncology with easily implementable Oncomine™ assays. Our latest development, the Ion Torrent™ Genexus™ system, provides a highly automated end-to-end workflow allowing laboratories to deliver NGS results in as little as one day.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational drugs designed to address key limitations of existing cancer therapies. Its lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. The company’s current pipeline of drug candidates also includes elzovantinib, targeting MET, CSF1R and SRC; TPX-0046, targeting RET; and TPX-0131, a next-generation ALK inhibitor. To learn more, visit www.tptherapeutics.com.
Wisepress.com, Europe’s leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you – Wisepress will deliver worldwide. In addition to attending 200 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers.
Keep up to date with Conference News & Alerts.